I don't say this often, but everything is lining up for this coin.
The Fed is easing. Liquidity is increasing. Trump's pro-crypto policies are accelerating. The GENIUS Act takes effect right now. Institutional barriers are falling.
That's the macro.
Now look at the coin itself:
Strong on-chain data. Growing network. Active development. Already being used by major institutions. And still trading at a price that doesn't reflect any of this.
When you get a macro tailwind AND strong fundamentals AND suppressed prices all at once?
That's rare. That's the kind of setup I've seen lead to gains of 3,500%... 8,600%... even higher.
I'm not saying it's guaranteed. Nothing is. But I've been doing this for 8 years, and I know what opportunity looks like.
This is it.
Your second chance could be here… get the details here now before the window closes.
Don't wait until the move has already started.
Bryce Paul
Crypto 101
Momentum Is Just Starting for These 3 Rapid-Growth Stocks in 2026
Written by Nathan Reiff. Originally Published: 2/2/2026.
At a Glance
- Corvus Pharmaceuticals has nearly tripled in value this year amid optimism that its atopic dermatitis drug candidate will continue to deliver strong trial results.
- Despite legal and other hurdles, New Era Energy & Digital recently noted a key achievement in its path toward providing data center capacity.
- USA Rare Earth has received around $1.6 billion in federal funding as it seeks to provide a domestic alternative to foreign rare earth minerals.
Nearly one month into 2026, the S&P 500 has been sluggish, rising just over 1% after multiple dips in January. But that middling performance masks several companies that have had a supercharged start to the year and dramatically outperformed the benchmark.
Investors looking to capitalize on rising momentum in 2026 might consider Corvus Pharmaceuticals Inc. (NASDAQ: CRVS), New Era Energy & Digital Inc. (NASDAQ: NUAI), and USA Rare Earth (NASDAQ: USAR), each of which has returned at least 56% year-to-date (YTD).
Analysts Stay Bullish on Corvus With 50%+ Upside Targets
Trump's Hand-Written Letter Will Shock his Haters (Ad)
A former U.S. government advisor has released a new briefing examining potential policy developments heading into 2026 and how they could influence markets.
The presentation focuses on historical context, upcoming milestones, and why some analysts believe next year could mark a significant turning point for long-term investors. It's designed to provide perspective and help readers understand what may be unfolding before it becomes widely discussed.
As a clinical-stage biopharma, Corvus operates in a sector prone to rapid, sizable price swings. A recent catalyst was positive data for soquelitinib, its drug candidate for atopic dermatitis and other conditions. In mid-January, Corvus reported promising Phase 1 results, including a 72% reduction in eczema severity among trial participants.
That news helped Corvus shares surge roughly 188% YTD. A Phase 2 trial is planned for early 2026 and could push the stock higher. To fund the upcoming study, Corvus launched a $150 million equity offering to extend its cash runway, though the move may dilute existing shareholders. This step was important because Corvus ended the third quarter of 2025 with only $67 million in cash.
Corvus is clearly banking on continued success with soquelitinib, and the addressable market for atopic dermatitis is large. Analysts remain optimistic: six of seven rate CRVS a Buy, and the consensus price target implies roughly 51% upside even after the recent run-up.
New Era's Data Center Pivot Makes Big Strides, Though Legal and Other Risks Remain
New Era & Digital is one of the more polarizing names in the energy and infrastructure space right now. Shares of NUAI are up more than 114% YTD after the company announced a partnership with Primary Digital Infrastructure to co-develop up to 1 gigawatt of hyperscale data center capacity — a key step in its pivot to the high-demand data center market. Earlier in the month, New Era closed the acquisition of a 50% ownership interest in Texas Critical Data Centers, further positioning it for that shift.
Those moves suggest New Era could execute on its reorganization, but the company also faces legal scrutiny: the Rosen Law Firm has announced plans to investigate allegations of "materially misleading business information." New Era is a relatively small company — with a market cap under $400 million — which raises the risk for investors. Still, those willing to accept these risks may be rewarded if the rally continues.
USA Rare Earth Looks to Fill a Significant Supply Chain Need With Government Support
Rare-earth minerals are increasingly vital across many technologies, and supply-chain and trade concerns threaten U.S. supplies. USA Rare Earth aims to address those concerns by building a domestic alternative. The company has been buoyed by a $1.6-billion investment from the federal government and additional private investments in recent weeks, on top of a strong cash position reported with its latest earnings.
The firm's rare-earth and magnet production capacity is expanding at its Texas operations, and revenues are expected to rise substantially. However, USA Rare Earth remains an early-stage company without a proven track record of profitability, which may deter some investors. Still, its 56% YTD gain and a strongly optimistic analyst profile suggest the stock could have significant upside.
This email communication is a sponsored message for Crypto 101 Media, a third-party advertiser of MarketBeat. Why was I sent this email message?.
© 2026 Boardwalk Flock LLC. All Rights Reserved.
2382 Camino Vida Roble, Suite I
Carlsbad, CA 92011, United States
The advice and strategies contained herein may not be suitable for your situation. You should consult with a professional where appropriate.
Readers acknowledge that the authors are not engaging in the rendering of legal, financial, medical, or professional advice. The reader agrees that under no circumstances Boardwalk Flock, LLC is responsible for any losses, direct or indirect, which are incurred as a result of the use of the information contained within this, including, but not limited to, errors, omissions, or inaccuracies.
Results may not be typical and may vary from person to person. Making money trading digital currencies takes time and hard work. There are inherent risks involved with investing, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk.
If you need assistance with your subscription, please contact our U.S. based support team at contact@marketbeat.com.
If you would no longer like to receive promotional emails from MarketBeat advertisers, you can unsubscribe or manage your mailing preferences here.
© 2006-2026 MarketBeat Media, LLC. All rights reserved.
345 N Reid Place #620, Sioux Falls, SD 57103. United States..
No comments:
Post a Comment